In contrast, a decrease in IL-2 concentrations during the trial (the mean trial level minus the baseline concentration) was associated with increased risk of any adenoma recurrence (lowest vs highest quartile of change in cytokine concentration: OR=1.68, 95% CI=1.13–2.49), whereas a decrease in IL-1β or IL-10 reduced the risk of advanced adenoma recurrence (OR=0.37, 95% CI=0.15–0.94 and OR=0.39, 95% CI=0.15–0.98, respectively; Table 3). The gene discussed is IL2; the disease is adenoma.